FIG. 1.

No abnormal changes in blood chemistry in NHP after a systemic rAAV9-hNAGLU vector delivery. NHP were treated with an IV injection of 1E13 vg/kg (a, Group 1, adult) or 2E13 vg/kg (b, Group 2, sexually immature) rAAV9-CMV-hNAGLU vector. Blood samples were assayed for blood chemistry panel before and after the vector delivery. AAV, adeno-associated virus; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate Aminotransferase; CK, creatine kinase; IV, intravenous; NHP, nonhuman primates; NT, nontreated controls; V, treated with vector only; V+P, treated with vector and immunosuppression.